Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 266-269 , July 2010

Escherichia coli resistance to quinolones at a comprehensive cancer center

  • Coralia N. Mihu

      Affiliations

    • The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author. Department of Infectious Diseases, Infection Control and Employee Health, The UT M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Tel.: +1-713-792-2972; fax: +1-713-794-4351.
    • ,
  • Paul R. Rhomberg

      Affiliations

    • Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • Jones Microbiology Institute Laboratories, North Liberty, IA 52317, USA
    • ,
  • Elizabeth Coyle

      Affiliations

    • University of Houston College of Pharmacy, Houston, TX 77204, USA
    • ,
  • Randall A. Prince

      Affiliations

    • University of Houston College of Pharmacy, Houston, TX 77204, USA
    • ,
  • Kenneth V. Rolston

      Affiliations

    • The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA

Received 6 November 2009 ,Accepted 14 February 2010.

References 

  1. Bucaneve G, Micozzi A, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.. N. Engl. J. Med. 2005;353:977–987
  2. Carratala J, Fernandez-Sevilla A, et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.. Clin. Infect. Dis. 1995;20:557–560discussion 561–3
  3. Cattaneo C, Quaresmini G, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution.. J. Antimicrob. Chemother. 2008;61:721–728
  4. Castanheira M, Mendes R, et al. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. medical centers; molecular evaluation from the MYSTIC Program (2007).. Microb. Drug Resist. 2008;14:211–216
  5. Cullen M, Steven N, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.. N. Engl. J. Med. 2005;353:988–998
  6. Gafter-Gvili A, Fraser A, et al. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.. Ann. Intern. Med. 2005;142(12 Pt 1):979–995
  7. Gafter-Gvili A, Paul M, et al. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis.. J. Antimicrob. Chemother. 2007;59:5–22
  8. Hughes WT, Armstrong D, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.. Clin. Infect. Dis. 2002;34:730–751
  9. Jacobson K, Rolston K, et al. Susceptibility surveillance among gram-negative bacilli at a cancer center.. Chemotherapy. 1999;45:325–334
  10. Kern WV, Andriof E, et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.. Antimicrob. Agents Chemother. 1994;38:681–687
  11. Mammeri H, Van De Loo M, et al. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe.. Antimicrob. Agents Chemother. 2005;49:71–76
  12. Park B, Courvalin P, et al. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.. Antimicrob. Agents Chemother. 2007;51:2464–2469
  13. Poirel L, Nguyen TV, et al. Plasmid-mediated quinolone resistance determinant qnrS in Enterobacter cloacae.. Clin. Microbiol. Infect. 2006;12:1021–1023
  14. Poirel L, Pitout JD, et al. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase.. Antimicrob. Agents Chemother. 2006;50:1525–1527
  15. Poirel L, Van De Loo M, et al. Association of plasmid-mediated quinolone resistance with extended-spectrum beta-lactamase VEB-1.. Antimicrob. Agents Chemother. 2005;49:3091–3094
  16. Tran JH, Jacoby GA. Mechanism of plasmid-mediated quinolone resistance.. Proc. Natl. Acad. Sci. U. S. A. 2002;99:5638–5642

☆ C.N.M., P.R.R., and K.V.R. have none to declare. E.C has received research funding from Cubist, is a consultant for Astellas and Cubist, and is on the speakers' bureau for Pfizer and Cubist. R.A.P. has received research support from Merck, Astellas, and Enzon. R.N.J. has received research/education grants from AB BIODISK, Abbott, API, Arpida, Astellas, AstraZeneca, Avexa, Bayer, bioMerieux, Cadence, Cempra, Cerexa, Cornerstone, Cubist, Daiichi, Elan, Elanco, Enanta, Forest, GlaxoSmithKline, Johnson & Johnson (Ortho McNeil), Merck, Novartis, Optimer, Ordway, Pacific Beach, Pfizer, Protez, Replidyne, Schering-Plough, Sequoia, Shionogi, Theravance, TREK Diagnostics, ViroPharma, and Wyeth.

PII: S0732-8893(10)00050-7

doi: 10.1016/j.diagmicrobio.2010.02.014

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 3 , Pages 266-269 , July 2010

Article Tools

* Image Usage & Resolution